HIGHLIGHTS
- who: Yanhao Liu from the Queen Mary University of London, United Kingdom have published the research work: Research landscape and trends of melanoma immunotherapy: A bibliometric analysis, in the Journal: (JOURNAL)
- what: The KETNOTE-029 phase 2 trial aimed to optimize the dosing schedule of dual-ICB. Based on the quantitative analysis of more than two thousand original articles, this study shows the research trends and hotspots and the results are repeatable, reliable, and convincing.
- how: The authors declare that the research was conducted in the absence of any commercial or financial relationships . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.